Authored By: Sarah
11 Jul 2024

 Immunotherapy Drugs Market to grow by USD 111.35 billion between 2024-2028

According to a research report “ Immunotherapy Drugs Market” by End-user (Hospitals, Clinics, Others) Type (Monoclonal antibodies, Vaccines, Immune checkpoint inhibitors, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 111.35 billion at a CAGR of  11.31% during the forecast period. The immunotherapy drugs market is experiencing significant growth due to the escalating global cancer burden. With cancer accounting for approximately 9.6 million annual fatalities according to the WHO, and projected cases set to increase by 50% within the next two decades as per IARC estimates, the demand for effective therapeutic solutions is paramount. Immunotherapy, which leverages the body's immune system to identify and eradicate cancer cells, is a promising response to this pressing health concern..

Browse market data tables, figures, and in-depth TOC on “Immunotherapy Drugs Market” by End-user (Hospitals, Clinics, Others) Type (Monoclonal antibodies, Vaccines, Immune checkpoint inhibitors, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By End-user, the Hospitals segment is projected to dominate the market size in 2024.

The immunotherapy drugs market is thriving, driven primarily by the success of monoclonal antibodies. These laboratory-produced antibodies selectively bind to proteins in cancer and immune cells, making them highly effective in treating various cancers and autoimmune disorders. The surge in monoclonal antibody drug development and approvals is a testament to their growing prevalence and efficacy. Factors fueling market expansion include technological advancements, the rising cancer incidence, and increased R&D investments.

By Type, Monoclonal antibodies  segment is expected to hold the largest market size for the year 2024.

In the dynamic healthcare landscape, hospitals serve as pivotal players in delivering advanced immunotherapy treatments. As pioneers in disease diagnosis and management, they offer unparalleled access to specialized expertise and state-of-the-art facilities. The integration of immunotherapy drugs into hospital care plans signifies a significant shift in the global healthcare market. These drugs, which stimulate the immune system to combat cancer cells, represent a targeted, potentially more effective treatment modality. Hospitals' commitment to incorporating immunotherapies ensures patients receive optimal care and innovation.

North America is forecasted to hold the largest market size by region in 2024.

The North American immunotherapy drugs market is experiencing significant growth, driven by the rising incidence of diseases and allergies, including cancer and tuberculosis. Food allergies represent a substantial investment segment, with approximately 32 million food-allergic individuals in the US and annual emergency care cases numbering 200,000. Despite this, there is currently no FDA-approved therapy available to address this unmet medical need, creating a substantial market opportunity.

The Immunotherapy Drugs Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Immatics NV
  • Incyte Corp.
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • ElevateBio
  • Genmab AS

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Immunotherapy Drugs Market encompasses a range of innovative treatments for various target diseases, including cancer, inflammatory diseases, and autoimmune diseases. Key players in this sector include biopharmaceutical companies developing immunotherapies such as Tecentriq, trastuzumab emtansine, and checkpoint inhibitors. These drugs harness the power of the body's immune system to combat diseases, making them a significant advancement in healthcare. Supportive government policies and research collaborations between industry and academia are driving the growth of this market. Biotechnology plays a crucial role in the development of immunotherapies, with a focus on targeted therapies like monoclonal antibodies and interferons and interleukins. The vaccines and biosimilars segments are also contributing to the market's expansion. The increasing prevalence of chronic diseases like cancer, rheumatoid arthritis, and organ failure necessitates substantial healthcare expenditure. Hospitals and clinics are at the forefront of administering these treatments, making the healthcare sector a key consumer of immunotherapy drugs. Infectious diseases are another area where immunotherapies are making a significant impact. Overall, the Immunotherapy Drugs Market is poised for robust growth in the coming years.

Market Research Overview

The Immunotherapy Drugs Market encompasses a broad spectrum of treatments, including mRNA-based vaccines for Geriatric population and infectious diseases like HIV, as well as monoclonal antibodies, interferons and interleukins, checkpoint inhibitors, and immunomodulators. These drugs play a pivotal role in addressing various chronic diseases, particularly those within the Cancer and Autoimmune Diseases segments. Key treatments in this market include Dupixent for Prurigo nodularis, belimumab for Lupus nephritis, Opdivo for Rheumatoid arthritis, Tecentriq for various cancers, and trastuzumab emtansine for Breast cancer. Side-effects, such as organ failure, are a concern for some patients undergoing immunotherapy, particularly those receiving chemotherapy. The Biopharmaceutical industry is at the forefront of research collaborations and advancements in this field, with a focus on targeted therapies for diseases like Colorectal, Breast, Prostate, and Lungs cancer. Supportive government policies and increased healthcare expenditure have fueled the growth of this market. Additionally, the emergence of biosimilars and the approval of new immunotherapy drugs by regulatory bodies like the European Medicines Agency (EMA) continue to shape the landscape of this dynamic market.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!